Iniparib: Preliminary Phase II data

Preliminary data from 17 evaluable patients in a single-arm, open-label, U.S. Phase II trial showed that IV BSI-201 plus gemcitabine and carboplatin produced an ORR of 70.6%. The trial plans to enroll 41 patients with epithelial ovarian carcinoma, fallopian tube cancer or primary peritoneal carcinoma. Patients are receiving gemcitabine and carboplatin on days 1 and 8 of each 21-day cycle, plus 5.6 mg/kg BSI-201 on days 1, 4, 8 and 11 of each cycle. Updated data from all 41 patients will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...